New York: Clarence Cigarette Company Expands Cannabis Research Program
A Clarence cigarette manufacturer says it has expanded its cannabis research program.
The 22nd Century Group said its wholly owned subsidiary, Botanical Genetics, has launched a number of new research projects to develop proprietary cannabis strains that have medical and agricultural uses.
Company officials estimate the markets for medical marijuana and industrial hemp – which they view as an ideal agricultural crop – could be worth up to $10 billion, and they said the company wants to be a leader in cannabis biotechnology.
“It’s amazing what you can do with this one plant,” said Paul Rushton, 22nd Century’s vice president for biotechnology.
Twenty-second Century first entered the marijuana market in 2014, when it acquired the U.S. license from Anandia Laboratories to a process that can adjust the potency of marijuana plants for medical and recreational use. That process is similar to the company’s existing technology that allowed it to alter...
This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.
Follow us on Instagram
Connect with us on Linkedin